Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE

This study has been completed.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Jane Armitage, University of Oxford
ClinicalTrials.gov Identifier:
NCT00461630
First received: April 17, 2007
Last updated: January 27, 2014
Last verified: January 2014

April 17, 2007
January 27, 2014
January 2007
October 2012   (final data collection date for primary outcome measure)
Major Vascular Event [ Time Frame: During scheduled treatment period (median duration 3.9 years) ] [ Designated as safety issue: No ]
Non-fatal myocardial infarction or coronary death, non-fatal or fatal stroke, or revascularisation
  • Time to first major vascular event
  • (defined as non-fatal myocardial infarction or coronary death
  • non-fatal or fatal stroke, or revascularisation) by the end of study
Complete list of historical versions of study NCT00461630 on ClinicalTrials.gov Archive Site
  • Major Coronary Events [ Time Frame: During scheduled treatment period (median duration 3.9 years) ] [ Designated as safety issue: No ]
    Non-fatal myocardial infarction (MI) or coronary death
  • Stroke [ Time Frame: During scheduled treatment period (median duration 3.9 years) ] [ Designated as safety issue: No ]
    Fatal or non-fatal
  • Coronary or Non-coronary Revascularisation [ Time Frame: During scheduled treatment period (median duration 3.9 years) ] [ Designated as safety issue: No ]
  • Mortality [ Time Frame: During scheduled treatment period (median duration 3.9 years) ] [ Designated as safety issue: No ]
    All-cause mortality
  • Major vascular events (non-fatal MI or cardiac death) by the end of the study
  • stroke (fatal or non-fatal) by the end of the study
  • Coronary or non-coronary revascularisation by the end of the study
  • Mortality, both overall and in particular categories of causes of death
  • Major cardiovascular events in people with a history of different diseases at the beginning of the study.
Not Provided
Not Provided
 
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant

The primary aim is to assess the effects of raising HDL cholesterol (the good type) with extended release niacin/laropiprant 2g (previously known as MK−0524A) versus matching placebo on the risk of heart attack or coronary death, stroke, or the need for arterial bypass procedures (revascularisation) in people with a history of circulatory problems. The secondary aim is to assess the effects of extended release niacin/laropiprant 2g daily on heart attack, coronary death, stroke, and revascularisation separately and to assess the effects on mortality both overall and in various categories of causes of death, and of the effects on major cardiovascular events in people with a history of different diseases at the beginning of the study.

Cardiovascular disease is one of the leading causes of morbidity and mortality in the United Kingdom (UK), as well as in the developed and the developing world. Finding new and safe treatments to reduce the burden of heart disease and strokes is therefore an important contribution to public health and in the wider public interest. HPS2-THRIVE aims to find out whether by combining niacin (a drug that has been available for 50 years) with a new drug laropiprant(which reduces the side-effects of niacin) is beneficial. All participants in HPS2-THRIVE will have established cardiovascular disease and therefore be at very high risk of recurrent vascular events (myocardial infarction, stroke or the need for arterial revascularisation). Two of the most important risk factors for recurrent events in such patients are the blood levels of LDL cholesterol with a positive association, and HDL cholesterol levels with a negative association.

HDL cholesterol has long been known to have a strong inverse correlation with coronary heart disease (CHD) risk. But, randomized trial evidence for beneficial effects from raising HDL cholesterol is limited. One of the most effective HDL-raising agents is niacin but the tolerability of niacin has been severely limited by flushing and cutaneous side-effects, which appear to be mediated largely by prostaglandin D. Laropiprant is a selective prostaglandin D receptor antagonist that substantially reduces the frequency and intensity of niacin-induced flushing. Daily oral doses of extended release (ER) niacin plus Laropiprant 2g(formerly MK-0524A) have been well tolerated in early studies and increase HDL cholesterol by 20-25%. The trial will assess whether this increase in HDL cholesterol translates into clinical benefit as is expected from the observational evidence. In addition, all participants will also be provided with effective LDL-lowering therapy, as either simvastatin 40mg daily alone or with ezetimibe 10mg daily in a combination tablet.

The complementary effects on the HDL (good) and LDL (bad) cholesterol produced by extended release niacin/laropiprant 2 g daily and simvastatin 40 mg with or without ezetimibe 10 mg should provide an excellent treatment option for patients with vascular disease. However, no trials so far have demonstrated clearly that raising HDL cholesterol produces the expected reduction in cardiovascular risk. If HPS2-THRIVE is able to demonstrate reliably that raising HDL cholesterol reduces the risk of further cardiovascular events then this will be relevant to hundreds of millions of people worldwide.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Cardiovascular Disease
  • Peripheral Arterial Disease
  • Diabetes Mellitus
  • Coronary Heart Disease
  • Drug: ER niacin/laropiprant
    Other Name: Tredaptive
  • Drug: simvastatin
    40 mg simvastatin tablet orally per day as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
    Other Name: Zocor
  • Drug: ezetimibe/simvastatin
    10 mg ezetimibe plus 40 mg simvastatin in single tablet taken once daily as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
    Other Names:
    • Inegy
    • Vytorin
  • Experimental: ER niacin/laropiprant
    1 g ER niacin plus 20 mg laropiprant per tablet. 2 tablets orally per day. With either 40 mg simvastatin tablet or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
    Interventions:
    • Drug: ER niacin/laropiprant
    • Drug: simvastatin
    • Drug: ezetimibe/simvastatin
  • Active Comparator: Placebo
    Placebo (for ER niacin/laropiprant) 2 tablets orally per day. With either 40 mg simvastatin tablet orally per day or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
    Interventions:
    • Drug: simvastatin
    • Drug: ezetimibe/simvastatin
HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014 Jul 17;371(3):203-12. doi: 10.1056/NEJMoa1300955.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25673
October 2012
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • History of myocardial infarction; or
  • Cerebrovascular atherosclerotic disease (history of presumed ischaemic stroke, transient ischaemic attack or carotid revascularisation)
  • Peripheral arterial disease (i.e. intermittent claudication or history of revascularisation); or
  • Diabetes mellitus with any of the above or with other evidence of symptomatic coronary heart disease (i.e. stable or unstable angina, or a history of coronary revascularisation or acute coronary syndrome).

Exclusion Criteria:

  • Age <50 or >80 years at invitation to Screening;
  • Less than 3 months since presentation with acute myocardial infarction, coronary syndrome or stroke (but such patients may be entered later, if appropriate);
  • Planned revascularisation procedure within 3 months after randomization (but such patients may be entered later, if appropriate);
  • Definite history of chronic liver disease, or abnormal liver function (i.e. Alanine transaminase (ALT) >1.5 times upper limit of normal (ULN). (Note: Patients with a history of acute hepatitis are eligible provided this ALT limit is not exceeded);
  • Breathlessness at rest for any reason;
  • Severe renal insufficiency (i.e. creatinine >200 µmol/L);
  • Evidence of active inflammatory muscle disease (e.g. dermatomyositis, polymyositis), or Creatine kinase (CK) >3 times upper limit of normal (3xULN);
  • Previous significant adverse reaction to a statin, ezetimibe, niacin or laropiprant;
  • Active peptic ulcer disease;
  • Concurrent treatment with:
  • fibric acid derivative ("fibrate")
  • niacin (nicotinic acid) at doses more than 100 mg daily
  • ezetimibe in combination with either simvastatin 80 mg, or atorvastatin 20-80 mg, or rosuvastatin 10-40 mg daily
  • any potent cytochrome P450 3A4 (CYP3A4) inhibitor, including: macrolide antibiotics (erythromycin, clarithromycin, telithromycin); systemic use of imidazole or triazole antifungals (e.g. itraconazole, ketoconazole); protease inhibitors (antiretroviral drugs for HIV infection); and nefazodone
  • ciclosporin
  • amiodarone
  • verapamil
  • danazol (Note: Patients who are temporarily taking such drugs may be re-screened when they discontinue them, if considered appropriate.);
  • Known to be poorly compliant with clinic visits or prescribed medication;
  • Medical history that might limit the individual's ability to take trial treatments for the duration of the study (e.g. severe respiratory disease, history of cancer or evidence of spread within last 5 years other than non-melanoma skin cancer, or recent history of alcohol or substance misuse)
Both
50 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00461630
CTSUTHRIVE1, ISRCTN29503772, 2006-001885-17
Yes
Jane Armitage, University of Oxford
University of Oxford
Merck Sharp & Dohme Corp.
Principal Investigator: Jane Armitage Clinical Trial Service Unit, University of Oxford
Principal Investigator: Colin Baigent Clinical Trial service Unit, University of Oxford
Principal Investigator: Zhengming Chen Clinical Trial Service Unit, University of Oxford
Principal Investigator: Martin Landray Clinical Trial Service Unit, University of Oxford
University of Oxford
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP